In particular, co-expression of TRF2 and VEGF-A correlates with a poor clinical outcome in CRC patients identifying a subset of patients (mainly stage II and III) at higher risk of disease relapse/progression that could take an effective advantage from specific therapeutic regimens, included pharmacological approaches based on administration of angiogenic inhibitors. Here, TERF2 is linked to colorectal carcinoma.